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Abstract: A high worldwide SARS-CoV-2 vaccine coverage must be attained to stop the COVID-19
pandemic. In this study, we assessed the level of willingness of Mozambicans to be vaccinated against
COVID-19. Data were collected between 11 and 20 March 2021, through a self-administered online
survey. Of the 1878 respondents, 30.1% were healthcare workers, 58.3% were aged between 18 and
35 years, 60% were male, and 38.5% were single. Up to 43% had been tested for COVID-19 and 29%
had tested positive. Overall vaccine acceptability was 71.4% (86.6% among healthcare workers, 64.8%
among other respondents; p < 0.001). Reasons for vaccine hesitancy included: fear of vaccine side
effects (29.6%) and the belief that the vaccine is not effective (52%). The acceptability of the SARS-
CoV-2 vaccine increased with increasing vaccine efficacy. Using logistic regression, determinants for
acceptability of the vaccine were: older age, a past COVID-19 test, a concern of becoming (re)infected
by COVID-19, having a chronic disease, and considering vaccination important for personal and
community health. In conclusion, vaccine acceptability in Mozambique was relatively high among
healthcare workers but significantly lower in the rest of the population. This suggests that there is a
need to educate the general population about SARS-CoV-2 vaccination and its importance.
Keywords: SARS-CoV-2; COVID-19; vaccine acceptability; Mozambique; online survey
1. Introduction
The new coronavirus (SARS-CoV-2) has caused a pandemic that destabilized health,
economy, and circulation of individuals worldwide. The first COVID-19 cases were de-
tected in China and the pandemic was declared in March 2020 [1]. By 12 June 2021, more
than 176 million people had been infected worldwide [2]. The African continent remains
the least affected, with a little over 5.0 million confirmed cases and 134,809 deaths. In
Mozambique, 71,461 confirmed cases of COVID-19 and 837 deaths have been reported [2].
Current measures against the disease aim to control transmission and include mainly
individual and community actions of improved hand hygiene, physical distancing, and
the use of face masks. However, a large-scale COVID-19 vaccination campaign across the
globe seems to be the only way out of this epidemic. Benefits of vaccination are multiple:
disease prevention, reduction of the severity and mortality of the disease, reduction of
the impact of the pandemic on the National Health System and the economy, mainly by
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protecting the most vulnerable groups [3]. As of 12 June, more than 2.36 billion vaccine
doses have already been administered worldwide [4]. However, there is a stark gap
between vaccination programs in different countries. As of 12 June, in Mozambique only
0.78% of the population received a first dose of a COVID-19 vaccine [2]. The process of
supplying vaccines to low- and middle-income countries remains a challenge. Difficulties
in increasing production and promoting equitable distribution of the SARS-CoV-2 vaccines
continue to be the main barrier to ending the pandemic [5].
The World Health organization adopted the Principles and Values Framework of
the Strategic Advisory Group of Experts on Immunization (SAGE) as the basis for the
worldwide roll-out of the COVID-19 vaccination campaign. These principles are based
on equal respect, global equity, national equity, reciprocity, and legitimacy [5,6]. The
SAGE proposes a roadmap for prioritizing uses of COVID-19 vaccines that considers
priority populations for vaccination based on epidemiologic setting and vaccine supply
scenarios. This roadmap builds on the WHO SAGE values framework for the allocation and
prioritization of COVID-19 vaccination. The rationale is minimization of the impact of the
pandemic on the main risk groups, the healthcare system, and society at large. Healthcare
workers, people in high-transmission environments, and people with medical conditions
such as diabetes, lung disease, heart disease, and obesity have been associated with worse
COVID-19 disease outcomes [5,6] and therefore should be vaccinated first.
In Mozambique, little is currently known about the acceptability of the SARS-CoV-2
vaccine by the population. The population’s perception of the vaccine will most likely be
influenced by their knowledge about the health consequences of SARS-CoV-2 infection and
the importance of the vaccine to prevent these consequences. This will in turn determine
vaccine acceptability by the population. Conducting this survey to investigate the percep-
tions of Mozambicans about COVID-19 vaccines and their willingness to be vaccinated is
important to plan the COVID-19 vaccination campaign in Mozambique.
2. Material and Methods
2.1. Study Setting and Design
A cross-sectional, self-administered electronic survey was conducted from 11 to 20
March 2021, among the general population of Mozambique. The study was part of a series
of online surveys organized by the International Citizen Project COVID-19 (ICPcovid; on-
line platform available at: https://www.icpcovid.com/en/covid-19-vaccination (accessed
on 22 July 2021) to investigate the acceptability of vaccines against COVID-19. The English
version of the ICPcovid online questionnaire was translated into Portuguese and adapted to
the local context by the Mozambican research team (Supplementary Material File S1). The
survey was launched by a team of health professionals from the National Institute of Health
in Mozambique. A snowball sampling approach was used, by sharing the questionnaire
through WhatsApp, institutional web pages (including the one for the Ministry of Health
of Mozambique), and other social networks, while asking participants to distribute the
questionnaire to their contacts.
2.2. Data Collection
Individuals aged 18 years and above who gave their informed e-consent (by ticking an
electronic checkbox) were able to participate in the survey. We collected socio-demographic
data, information about underlying health conditions, acceptability of the COVID-19
vaccine, and associated factors such as vaccine efficacy, vaccine origin, and brand of the
vaccine.
A 5-point Likert scale was used to assess the participant’s concern about becoming
(re)infected with SARS-CoV-2 during the ongoing outbreak and determinants for acceptabil-
ity; scores ranged from 1 (minimum level of fear, concern, or difficulty) to 5 (highest level).
All responses were sent anonymously to the ICPcovid platform, stored on a password
protected server in Belgium until the data were extracted for analysis.
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2.3. Data Analysis
Descriptive statistics were presented as percentages (%) for categorical variables;
continuous variables such as age were also categorized into age groups. A multiple logistic
regression model was built to investigate factors associated with acceptability of the vaccine.
The dependent variable was “vaccine acceptability: Yes versus no” [7]. Age and gender
were introduced into the model to account for the population’s demographics, and all other
covariates which had a p-value below 0.25 during univariate analysis were also included
in the final model.
2.4. Ethical Considerations
The study protocol was approved by the Institutional Bioethics Committee of the
National Institute of Health of Mozambique (Ref: 31/CIBS-INS/2021) and by the Ethics
Committee of the University of Antwerp (Ref: 20/13/148).
3. Results
3.1. Socio-Demographic Characteristics of the Participants
The responses of 1878 participants were included in the analysis. Most respondents
were in the 18–35 age group (58.3%), the majority were male (60%), and 38.5% were single
(Table 1).
Table 1. Socio-demographic characteristics of the participants.
Characteristics Number (%)N = 1878
Age
18–35 years 1095 (58.3%)
36–60 years 719 (38.3%)









3.2. Participants’ Health Characteristics
Overall, 43% (808) had been tested for COVID-19, and in 28.8% (233), the test result
was positive. More healthcare workers had been COVID-19 tested (57.2%) compared to
non-healthcare workers (37.0%); p < 0.001. Among respondents who reported COVID-19
test results, positivity rate was similar among the 324 healthcare workers (28.4%) and
the 485 non-healthcare workers (29.1%); p = 0.854. Six hundred twenty-three (33.2%)
participants were reported to suffer from a chronic disease (Table 2).
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Table 2. Participants’ health characteristics.
Characteristics Number (%)N = 1878
Tested for COVID-19 (entire sample)
Yes 809 (43.0%)
No 1069 (57.0%)
Tested for COVID-19 (healthcare workers)
Yes 324 (57.2%)
No 242 (42.8%)
Tested for COVID-19 (other participants)
Yes 485 (37.0%)
No 827 (63.0%)


















Respiratory diseases 147 (7.8%)
Stroke 2 (0.1%)
Other 173 (9.2%)
I do not suffer from any chronic disease 1257 (66.9%)
3.3. Acceptability of the Vaccine against COVID-19
Of all the study participants, 1340 (71.4%) would agree to take the SARS-CoV-2
vaccine. Acceptance was higher among healthcare workers (86.6%) compared to the
general population (64.9%); p < 0.001 (Table 3). Reasons for vaccine hesitancy included:
belief that the vaccine is not effective (52.0%); fear of side effects of the vaccine (29.6%);
beliefs that the vaccine was made to cause harm (1.8%). To consider accepting vaccination
against SARS-CoV-2, 204 (15.2%) would consider the brand (manufacturer), 320 (23.9%)
its country of origin, 559 (41.7%) other aspects, and 258 (19.3%) did not have an opinion
on what to consider before accepting the vaccine. We also observed that the greater the
reported efficacy of the vaccine, the more respondents would be likely to accept it. Of
the participants who would accept the vaccine, 38.7% would accept the vaccine if it were
50% to 60% efficacious, while up to 89.5% would accept the vaccine if it were at least 90%
efficacious (Table 3).
3.4. Factors Associated with Acceptability of the Vaccine against COVID-19
In multivariable analysis, subjects above 60 years and healthcare workers were more
likely to accept the SARS-CoV-2 vaccine. Irrespective of the COVID test result, participants
who had previously been tested for COVID-19 were more willing to take the vaccine
compared to those who were never tested (Table 4). Moreover, participants who were
“extremely concerned” about COVID-19 (re)infection and those who suffered from a chronic
disease had higher odds of accepting the SARS-CoV-2 vaccine. Finally, participants who
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considered vaccination important for their own health or for the health of the community
were more willing to accept vaccination, compared to those who considered vaccination
not or less important.
Table 3. Acceptability of the vaccine against COVID-19.
Characteristics Number (%) ParticipantsN = 1878
Vaccine acceptability (entire sample)
Yes 1340 (71.4%)
No 538 (28.6%)
Vaccine acceptability (healthcare workers)
Yes 490 (86.6%)
No 76 (13.4%)
Vaccine Acceptability (Other participants)
Yes 850 (64.8%)
No 462 (35.2%)
Reasons for vaccine hesitancy +
I’m afraid of the side effects of the vaccine 159 (29.6%)
I think the vaccine is not effective 280 (52.0%)
I think the vaccine was made to harm us 34 (6.3%)
My body is naturally strong, I don’t need a vaccine 6 (1.1%)
Respiratory diseases 2 (0.4%)
I already had COVID-19, so I think I am immune to the disease 1 (0.2%)
I do not think COVID-19 exists 7 (1.3%)
Other reason 49 (9.1%)
What would determine your vaccine acceptance *
Vaccine origin 320 (23.9%)
Vaccine brand 204 (15.2%)
Other aspects 559 (41.7%)
No opinion 258 (19.3%)
Vaccine acceptability according to vaccine efficacy *
50% to 60% 518 (38.7%)
60% to 70% 648 (48.4%)
70% to 80% 879 (65.6%)
80% to 90% 1050 (78.4%)
90% + 1199 (89.5%)
+ Percentages are calculated with the total number of participants who would not accept the vaccine as de-
nominator. * Percentages are calculated with the total number of participants who would accept the vaccine as
denominator.
Table 4. Multiple logistic regression model investigating predictors for COVID-19 vaccine acceptabil-
ity.
Covariate Adjusted OR (95% CI) p-Value
Age
>60 years Ref
36–60 years 0.30 (0.09–0.83) 0.035
18–35 years 0.22 (0.06–0.61) 0.008
Sex
Male Ref
Female 0.80 (0.60–1.06) 0.122
Marital status
Single Ref
Married 1.31 (0.92–1.86) 0.136
Other 0.80 (0.38–1.78) 0.572
Cohabitation 0.72 (0.50–1.05) 0.083
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Table 4. Cont.
Covariate Adjusted OR (95% CI) p-Value
Type of respondents
Healthcare workers Ref
Non-healthcare workers (general population) 0.31 (0.22–0.44) <0.001
Previously tested for COVID-19
Yes Ref
No 0.63 (0.45–0.88) 0.008
What was the test result?
Negative Ref
Positive 0.75 (0.46–1.23) 0.248
Unknown 1.14 (0.41–3.79) 0.811
Level of worry /concern about becoming
(re)infected with the SARS-CoV-2 virus (Likert scale)
Extremely concerned Ref
Very concerned 1.04 (0.79–1.37) 0.784
Moderately concerned 0.63 (0.44–0.91) 0.014
A little concerned 0.71 (0.43–1.16) 0.162
Not at all concerned 0.29 (0.19–0.45) <0.001
Chronic disease
I do not suffer from chronic disease Ref
I suffer from chronic illness 1.25 (1–1.55) 0.048
Importance of vaccination for your health
Important Ref
Moderate 0.62 (0.50–0.92) 0.012
Not important 0.04 (0.03–0.05) <0.001
Importance of vaccination for community health
Important Ref
Moderate 0.71 (0.53–0.95) 0.021
Not important 0.05 (0.04–0.06) <0.001
OR: odds ratio; CI: confidence interval; Ref: reference category.
4. Discussion
High worldwide SARS-CoV-2 vaccine coverage is required to attain a sufficiently high
population level of “herd immunity” that would stop the COVID-19 pandemic. This means
that in the African continent (including Mozambique), high SARS-CoV-2 vaccine coverage
would also need to be reached. Our online survey showed an overall vaccine acceptability
rate of 71.4% among Mozambican study participants. Acceptability was relatively high
among healthcare workers (86.6%) but significantly lower in the general population (64.8%).
Such higher vaccine acceptance among healthcare workers was also reported in a recent
survey in Somalia [8] and the Eastern Cape in South Africa [9], but surprisingly in the
Democratic Republic of Congo (DRC), healthcare workers were less willing to receive
a COVID-19 vaccine [10]. In a recent systematic review of COVID-19 vaccine hesitancy
worldwide, in 62% of the surveys among the general public, the acceptance of COVID-19
vaccination was at least 70% [11]. However, low rates of COVID-19 vaccine acceptance
were reported in the Middle East (for example in Kuwait (23.6%), Jordan (28.4%), and Saudi
Arabia (64.7%), Russia (54.9%), and certain African and European countries [10,12,13]. In
Qatar, a Nationally Representative Survey of Qatari Nationals and Migrants conducted
between December 2020 and January 2021 using phone interviews showed that 42.7%
(95% CI: 39.5–46.1) accepted being vaccinated with a COVID-19 vaccine, 45.2% (95% CI:
41.9–48.4) were hesitant, and 12.1% (95% CI: 10.1–14.4) were resistant [14]. In South
Africa, vaccine acceptance rates were assessed in nine surveys showing rates varying
between 52 and 82% [15]. In other African countries, vaccine acceptance rates were 88% in
Egypt [16] and 74.5% in Nigeria [17] but only 54.1% in Ghana [18], 53.6% in Uganda [19],
and 46.1% in Ethiopia [20]. Of the eight studies conducted among healthcare workers,
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three surveys reported vaccine acceptance rates below 60%, with the lowest acceptance rate
in the DRC (27%) [11,21]. The higher vaccine acceptance rate among healthcare workers
in Mozambique is a positive finding, as it has been shown that healthcare workers could
increase the confidence of the general population in the vaccine by informing them about
its safety and efficacy. When healthcare professionals are vaccine-confident and vaccinate
themselves, they are more likely to recommend vaccination to their patients.
Our study found that vaccine acceptability increased with vaccine efficacy, corroborat-
ing recent findings from an international survey [22]; the latter was conducted in several
other low- and middle-income countries, and revealed that for a COVID-19 vaccine that
is 90% effective, the vaccine acceptance rate in Brazil was 88.9%, in Thailand 58.5%, in
Malaysia 55.4%, in Uganda 65.4%, but was very low in many other African countries, such
as 32.9% in the DRC, and 22.6% in Benin [22]. Thus COVID-19 vaccine hesitancy is a global
phenomenon complicating the vaccine roll-out in different countries and continents.
Our study showed that the lower the age, the lower the vaccine acceptability. This
was also found in Saudi Arabia [23] and South Africa [15]. This is an important finding,
as advanced age is a risk factor for severe COVID-19 disease and, therefore, vaccine
acceptability by the elderly is crucial to prevent severe disease, hospitalizations, and
death [5,24]. However, in a study in Ghana, persons 36–45 years of age were less likely
to accept being vaccinated compared to those aged 18–25 years [18]. Once again, this
shows that acceptability varies by country, region, culture, and that some determinants
differ depending on context. In the same light, suffering from a chronic disease was a
determinant for increased vaccine acceptability as was observed in Egypt but not in several
other low- and middle-income countries [22].
Participants who considered vaccination important for their own health or for the
health of the community were more willing to accept vaccination. This suggests that if
more people are educated about the importance of vaccination against COVID-19, their
willingness to be vaccinated will increase. Our findings are similar to an online study
conducted in China which showed that 76.6% of the participants believed the vaccine
would be beneficial for their health [25]. Gender, marital status, and the result of the
COVID-19 test were not associated with vaccine availability as was reported in a survey in
the DRC [10]. However, a recent survey in several low- and middle-income countries [22]
and a survey in Somalia [8] showed that being a female reduced the odds for COVID-19
vaccine acceptance [8,22]. Moreover, in a systematic review of nationally representative
samples in high-income countries, being male, older, high-income, highly educated, and
belonging to a majority ethnic group were consistently associated with greater likelihood
of having the intention to be vaccinated [26].
Increasing COVID-19 vaccine acceptance will require involving many stakeholders.
Non-governmental and civil society organizations as well as influential faith and cultural
leaders, could play a crucial role in motivating communities to increase acceptance of
COVID-19 vaccination. To reach high COVID-19 vaccination coverage in Africa will be
challenging. However, this COVID-19 pandemic is also a unique opportunity to demon-
strate the importance of vaccination for public health.
5. Study Limitations
Our study population cannot be representative of the general population of Mozam-
bique. Indeed, individuals without access to the internet (i.e., people with less education
and belonging to lower social classes) did not have the opportunity to participate in the
survey. Many studies have documented that a lower level of education was associated with
lower vaccine acceptance [9,13,17,27–29]. Moreover, a large proportion of the respondents
were healthcare workers. The latter is most likely the effect of the way the survey was
launched, mainly by investigators with a medical background and using a snowballing
approach. We therefore presented stratified results to disentangle the responses from
healthcare workers and other respondents. Moreover, not everybody in Mozambique was
aware of the survey. Similar to the survey conducted in high-income countries [26], it
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is important that, in low-income countries as well, vaccine acceptability studies should
be organized on a representative sample of the population. We must also emphasize the
cross-sectional design of our study, which implies that we only present a snapshot of the
situation at the time of the survey. Perceptions about vaccines can change rapidly and are
influenced by social media among other factors. It is important to note that our survey
was carried out before the rare side effects of the AstraZeneca and the J&J vaccine became
known and were widely publicized.
6. Conclusions
This survey in Mozambique showed that vaccine acceptability was relatively high
among healthcare workers but significantly lower in the rest of the population. SARS-CoV-2
vaccination is still to start in Mozambique. COVID-19 vaccine roll-out programs must
engage all stakeholders to ensure that communities are correctly informed. In Mozambique
it is recommended to intensify the mobilization for COVID-19 vaccination, conveying
positive messages regarding the efficacy and side effects of the vaccine to reduce fear and
increase acceptability. It is expected that the rate of vaccination hesitancy will decrease once
the population experiences the vaccination rolling out as being well organized and that
people do not experience serious side effects. Currently, as in many other African countries,
Mozambique is facing a serious third COVID-19 wave driven by the Delta variant [30].
However, less than 7000 COVID-19 vaccines are administered per day [31]. This rate will
have to be increased quickly to reduce COVID-19 related mortality.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9080828/s1, File S1: Survey Questionnaire, PDF.
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